The autoinjectors market would grow at a CAGR of 20.32% over the predicted time frame. The market is expected to increase in value from US$ 56.31 Bn in 2022 to US$ 247.3 Bn in 2030.
The on autoinjectors Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2288
A recent report provides crucial insights along with application based and forecast information in the Global Autoinjectors Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Autoinjectors market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Autoinjectors market are included as given below:
Autoinjectors Market Key Players are: AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, Antares Pharma, GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceutical, Merck KGaA
Market Segments
By Therapy
- Rheumatoid Arthritis
- Multiple Sclerosis
- Diabetes
- Anaphylaxis
- Other Therapies
By Type
- Disposable
- Reusable
By Route of Administration
- Subcutaneous
- Intramuscular
By Type of Molecule
- Monoclonal Antibody
- Peptide
- Protein
- Small Molecule
By End-User
- Home Care Settings
- Hospitals & Clinics
- Ambulatory Care Settings
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global autoinjectors market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the autoinjectors market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Autoinjectors Market
5.1. COVID-19 Landscape: Autoinjectors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Autoinjectors Market, By Therapy
8.1. Autoinjectors Market, by Therapy, 2022-2030
8.1.1. Rheumatoid Arthritis
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Multiple Sclerosis
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Diabetes
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Anaphylaxis
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Other Therapies
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Autoinjectors Market, By Type
9.1. Autoinjectors Market, by Type, 2022-2030
9.1.1. Disposable
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Reusable
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Autoinjectors Market, By Route of Administration
10.1. Autoinjectors Market, by Route of Administration, 2022-2030
10.1.1. Subcutaneous
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Intramuscular
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Autoinjectors Market, By Type of Molecule
11.1. Autoinjectors Market, by Type of Molecule, 2022-2030
11.1.1. Monoclonal Antibody
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Peptide
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Protein
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Small Molecule
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Autoinjectors Market, By End-User
12.1. Autoinjectors Market, by End-User, 2022-2030
12.1.1. Home Care Settings
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Hospitals & Clinics
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Ambulatory Care Settings
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Autoinjectors Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.1.2. Market Revenue and Forecast, by Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.1.5. Market Revenue and Forecast, by End-User (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.1.6.5. Market Revenue and Forecast, by End-User (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.1.7.5. Market Revenue and Forecast, by End-User (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.2. Market Revenue and Forecast, by Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.5. Market Revenue and Forecast, by End-User (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.7. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.8. Market Revenue and Forecast, by End-User (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.10. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.11. Market Revenue and Forecast, by End-User (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Type (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.13. Market Revenue and Forecast, by End-User (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Type (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.15. Market Revenue and Forecast, by End-User (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.2. Market Revenue and Forecast, by Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.5. Market Revenue and Forecast, by End-User (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.7. Market Revenue and Forecast, by End-User (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.9. Market Revenue and Forecast, by End-User (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Type (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.10.5. Market Revenue and Forecast, by End-User (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Type (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.11.5. Market Revenue and Forecast, by End-User (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.2. Market Revenue and Forecast, by Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.5. Market Revenue and Forecast, by End-User (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.7. Market Revenue and Forecast, by End-User (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.9. Market Revenue and Forecast, by End-User (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Type (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.10.5. Market Revenue and Forecast, by End-User (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Type (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.11.5. Market Revenue and Forecast, by End-User (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.5.2. Market Revenue and Forecast, by Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.5.5. Market Revenue and Forecast, by End-User (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.5.7. Market Revenue and Forecast, by End-User (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Type (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.5.8.5. Market Revenue and Forecast, by End-User (2017-2030)
Chapter 14. Company Profiles
14.1. AbbVie Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Mylan
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Eli Lilly and Company
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Ypsomed
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Amgen
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Becton
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Dickinson and Company
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Antares Pharma
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. GlaxoSmithKline plc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Johnson & Johnson
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments